Operating Income (Loss) of ANAVEX LIFE SCIENCES CORP. from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
ANAVEX LIFE SCIENCES CORP. quarterly and annual Operating Income (Loss) in USD history and change rate from 30 Jun 2010 to 31 Dec 2025.
  • ANAVEX LIFE SCIENCES CORP. Operating Income (Loss) for the quarter ending 31 Dec 2025 was $6,782,000, a 50% increase year-over-year.
  • ANAVEX LIFE SCIENCES CORP. Operating Income (Loss) for the twelve months ending 31 Dec 2025 was $44,598,000, a 19% increase year-over-year.
  • ANAVEX LIFE SCIENCES CORP. annual Operating Income (Loss) for 2025 was $51,408,000, a 2.8% increase from 2024.
  • ANAVEX LIFE SCIENCES CORP. annual Operating Income (Loss) for 2024 was $52,877,000, a 5.2% increase from 2023.
  • ANAVEX LIFE SCIENCES CORP. annual Operating Income (Loss) for 2023 was $55,763,000, a 9.4% decline from 2022.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

ANAVEX LIFE SCIENCES CORP. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $44,598,000 $6,782,000 +$6,810,000 +50% 01 Oct 2025 31 Dec 2025 10-Q 09 Feb 2026 2026 Q1
Q3 2025 $51,408,000 $10,844,000 +$3,428,000 +24% 01 Jul 2025 30 Sep 2025 10-K 25 Nov 2025 2025 FY
Q2 2025 $54,836,000 $14,459,000 +$144,000 +0.99% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q3
Q1 2025 $54,980,000 $12,513,000 +$111,000 +0.88% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q2
Q4 2024 $55,091,000 $13,592,000 -$2,214,000 -19% 01 Oct 2024 31 Dec 2024 10-Q 09 Feb 2026 2026 Q1
Q3 2024 $52,877,000 $14,272,000 -$1,614,000 -13% 01 Jul 2024 30 Sep 2024 10-K 25 Nov 2025 2025 FY
Q2 2024 $51,263,000 $14,603,000 -$1,072,000 -7.9% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q3
Q1 2024 $50,191,000 $12,624,000 +$1,566,000 +11% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q2
Q4 2023 $51,757,000 $11,378,000 +$4,006,000 +26% 01 Oct 2023 31 Dec 2023 10-Q 12 Feb 2025 2025 Q1
Q3 2023 $55,763,000 $12,658,000 +$2,626,143 +17% 01 Jul 2023 30 Sep 2023 10-K 25 Nov 2025 2025 FY
Q2 2023 $58,389,143 $13,531,000 -$1,072,280 -8.6% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q3
Q1 2023 $57,316,863 $14,190,000 -$2,670,253 -23% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q2
Q4 2022 $54,646,610 $15,384,000 -$3,660,610 -31% 01 Oct 2022 31 Dec 2022 10-Q 07 Feb 2024 2024 Q1
Q3 2022 $50,986,000 $15,284,143 01 Jul 2022 30 Sep 2022 10-K 27 Nov 2023 2023 FY
Q2 2022 $12,458,720 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q3
Q1 2022 $11,519,747 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q2
Q4 2021 $11,723,390 01 Oct 2021 31 Dec 2021 10-Q 07 Feb 2023 2023 Q1
Q2 2015 $3,781,344 $1,512,960 -$514,127 -51% 01 Apr 2015 30 Jun 2015 10-Q 14 Aug 2015 2015 Q3
Q1 2015 $3,267,217 $858,339 +$162,828 +16% 01 Jan 2015 31 Mar 2015 10-Q 14 May 2015 2015 Q2
Q4 2014 $3,430,045 $770,678 -$461,070 -149% 01 Oct 2014 31 Dec 2014 10-Q 17 Feb 2015 2015 Q1
Q3 2014 $2,968,975 $639,367 +$829,040 +56% 01 Jul 2014 30 Sep 2014 10-K 29 Dec 2014 2014 FY
Q2 2014 $3,798,015 $998,833 -$872,851 -693% 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015 2015 Q3
Q1 2014 $2,925,164 $1,021,167 -$894,056 -703% 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q2
Q4 2013 $2,031,108 $309,608 +$106,259 +26% 01 Oct 2013 31 Dec 2013 10-Q 17 Feb 2015 2015 Q1
Q3 2013 $2,137,367 $1,468,407 -$829,052 -130% 01 Jul 2013 30 Sep 2013 10-K 29 Dec 2014 2014 FY
Q2 2013 $1,308,315 $125,982 +$571,931 +82% 01 Apr 2013 30 Jun 2013 10-Q 13 Aug 2014 2014 Q3
Q1 2013 $1,880,246 $127,111 +$668,495 +84% 01 Jan 2013 31 Mar 2013 10-Q/A 30 May 2014 2014 Q2
Q4 2012 $2,548,741 $415,867 +$1,772,750 +81% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014 2014 Q1
Q3 2012 $4,321,491 $639,355 +$587,219 +48% 01 Jul 2012 30 Sep 2012 10-K 30 Dec 2013 2013 FY
Q2 2012 $4,908,710 $697,913 +$939,225 +57% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013 2013 Q3
Q1 2012 $5,847,935 $795,606 +$1,152,119 +59% 01 Jan 2012 31 Mar 2012 10-Q 17 May 2013 2013 Q2
Q4 2011 $7,000,054 $2,188,617 -$819,472 -60% 01 Oct 2011 31 Dec 2011 10-Q 14 Feb 2013 2013 Q1
Q3 2011 $6,180,582 $1,226,574 01 Jul 2011 30 Sep 2011 10-K 31 Dec 2012 2012 FY
Q2 2011 $1,637,138 -$334,274 -26% 01 Apr 2011 30 Jun 2011 10-Q 17 Aug 2012 2012 Q3
Q1 2011 $1,947,725 01 Jan 2011 31 Mar 2011 10-Q 15 May 2012 2012 Q2
Q4 2010 $1,369,145 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012 2012 Q1
Q2 2010 $1,302,864 01 Apr 2010 30 Jun 2010 10-Q 12 Aug 2011 2011 Q3

ANAVEX LIFE SCIENCES CORP. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $51,408,000 +$1,469,000 +2.8% 01 Oct 2024 30 Sep 2025 10-K 25 Nov 2025 2025 FY
2024 $52,877,000 +$2,886,000 +5.2% 01 Oct 2023 30 Sep 2024 10-K 25 Nov 2025 2025 FY
2023 $55,763,000 -$4,777,000 -9.4% 01 Oct 2022 30 Sep 2023 10-K 25 Nov 2025 2025 FY
2022 $50,986,000 -$8,984,000 -21% 01 Oct 2021 30 Sep 2022 10-K 27 Nov 2023 2023 FY
2021 $42,002,000 -$10,913,768 -35% 01 Oct 2020 30 Sep 2021 10-K 27 Nov 2023 2023 FY
2020 $31,088,232 01 Oct 2019 30 Sep 2020 10-K 28 Nov 2022 2022 FY
2014 $2,968,975 -$831,608 -39% 01 Oct 2013 30 Sep 2014 10-K 29 Dec 2014 2014 FY
2013 $2,137,367 +$2,184,124 +51% 01 Oct 2012 30 Sep 2013 10-K 29 Dec 2014 2014 FY
2012 $4,321,491 +$1,859,091 +30% 01 Oct 2011 30 Sep 2012 10-K 30 Dec 2013 2013 FY
2011 $6,180,582 -$532,314 -9.4% 01 Oct 2010 30 Sep 2011 10-K 31 Dec 2012 2012 FY
2010 $5,648,268 01 Oct 2009 30 Sep 2010 10-K 22 Dec 2011 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.